Effect of atorvastatin on highdensity lipoprotein cholesteroland its relationship withcoronary events: a subgroupanalysis of the GREekAtorvastatin and Coronary-heart-disease Evaluation (GREACE) Study

References

• Castelli WP, Doyle JT, Gordon T, et al. HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation 1997;55:767–72
   Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four Prospective American Studies. Circulation 1989;79:8–15
   PubMed Web of Science ®Google Scholar
• Assmann G, Schulte H, von Eckardstein A, Huang Y. High density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124:S11–S20
   Web of Science ®Google Scholar
• Rifkind BM. High-density lipoprotein cholesterol and coronary artery disease: survey of the evidence. Am J Cardiol 1990;66:3A–6A
   Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. New Engl J Med 1999;341:410–8
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998;97:1453–60
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Herd JA, Ferlic LL, et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 1999;99:736–43
   PubMed Web of Science ®Google Scholar
• Furberg CD, Herrington DM, Psaty BM. Are drugs within a class interchangeable? Lancet 1999;354:1202–4
   Google Scholar
• Wierzbicki AS. Editorial. Is a statin a statin? Int J Clin Pract 2001;55:78–80
   Google Scholar
• Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goals versus usual care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 2002;18:220–8
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994;89:1333–445
   PubMed Web of Science ®Google Scholar
• Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486–97
   PubMed Web of Science ®Google Scholar
• Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41
   PubMed Web of Science ®Google Scholar
• Sacks FM, for the Expert Group on HDL Cholesterol. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: Expert Group Recommendations. Am J Cardiol 2002;90:139–43
   Google Scholar
• Athyros VG, Papageorgiou AA, Symeonidis AN, et al. Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Angiology 2003;54:679–90
   Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. J Clin Pathol [in press]
   Google Scholar
• Athyros VG, Elisaf N, Papageorgiou AA, et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease. A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Am J Kidney Dis [in press]
   Google Scholar
• Crouse JR, Frohlich J, Ose L, Mercuri M, Tobert JA. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiol 1999;83:1476–7
   Google Scholar
• Wierzbicki AS, Lumb PJ, Semra YK, Chik G, Christ ER, Crook MA. Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias. Quart J Med 1999;92:387–94
   Google Scholar
• Wierzbicki AS, Lumb PJ, Chik G, Crook M. Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolemia. Int J Clin Pract 1999;53:609–11
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Isaacsohn JL, Ose L, et al. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol 2000;86:221–3
   PubMed Web of Science ®Google Scholar
• Illingworth DR, Crouse JR 3rd, Hunninghake DB, et al; Simvastatin Atorvastatin HDL Study Group. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin 2001;17:43–50
   Google Scholar
• Recto CS, Acosta S, Dobs A. Comparison of the efficacy and tolerability of simvastatin and atorvastatin in the treatment of hypercholesterolaemia. Clin Cardiol 2000;23:682–8
   Google Scholar
• Jones P, Kafonek S, Laurora I, for the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES Study). Am J Cardiol 1998;81:582–7
   Google Scholar
• Simons LA. Comparison of atorvastatin alone versus simvastatin ± cholestyramine in the management of severe primary hypercholesterolaemia (The Six Cities Study). Aust New Zealand J Med 1998;28:327–33
   PubMedGoogle Scholar
• Wierzbicki AS, Mikhailidis DP. Dose–response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies. Int J Cardiol 2002;84:52–7
   Web of Science ®Google Scholar
• Branchi A, Fiorenza AM, Torri A, et al. Atorvastatin increases HDL cholesterol in hypercholesterolemic patients. Evidence of a relationship with baseline HDL cholesterol. Nutr Metab Cardiovasc Dis 2002;12:24–8
   PubMed Web of Science ®Google Scholar
• Guerin M, Egger P, Soudant C, et al. Dose-dependent action of atorvastatin in type IIB hyperlipidaemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis 2002;163:287–96
   PubMed Web of Science ®Google Scholar
• Hoogerbrugge N, Jansen H. Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia. Atherosclerosis 1999;146:167–74
   PubMed Web of Science ®Google Scholar
• Schaefer E, McNamara J, Tayler T, et al. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. Am J Cardiol 2002;90:689–96
   PubMed Web of Science ®Google Scholar
• Sasaki J, Kumagae G, Sata T, Ikeda M, Tsutsumi S, Arakawa K. Seasonal variation of serum high density lipoprotein cholesterol levels in men. Atherosclerosis 1983;48:167–72
   PubMed Web of Science ®Google Scholar
• Insull W, Kafonek S, Goldner D, Zieve F. Comparison of efficacy and safety of atorvastatin (10 mg) with simvastatin (10 mg) at 6 weeks. ASSET Investigators. Am J Cardiol 2001;87:554–9
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlöf B, Poulter N, et al., for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149–58
   Google Scholar
• Dart A, Jerums G, Nicholson G, et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997;80:39–44
   PubMed Web of Science ®Google Scholar
• Smilde TJ, van den Berkmortel FW, Wollersheim H, van Langen H, Kastelein JJ, Stalenhoef AF. The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia. Eur J Clin Invest 2000;30:473–80
   PubMed Web of Science ®Google Scholar
• Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357: 577–81
   PubMed Web of Science ®Google Scholar
• Alagona C, Soro A, Ylitalo K, Salonen R, Salonen JT, Taskinen MR. A low high density lipoprotein (HDL) level is associated with carotid artery intima-media thickness in asymptomatic members of low HDL families. Atherosclerosis 2002;165:309–16
   PubMed Web of Science ®Google Scholar
• Saku K, Zhang B, Ohta T, Arakawa K. Quantity and function of high density lipoprotein as an indicator of coronary atherosclerosis. J Am Coll Cardiol 1999;33:436–43
   PubMed Web of Science ®Google Scholar
• Tall AR. An overview of reverse cholesterol transport. Eur Heart J 1998;19:A31–5
   PubMed Web of Science ®Google Scholar
• Johnson WJ, Mahlberg FH, Rothblat GH, Phillips MC. Cholesterol transport between cells and high-density lipoproteins. Biochim Biophys Acta 1991;1085: 273–98
   PubMed Web of Science ®Google Scholar
• Dobiasova M, Frohlich JJ. Structural and functional assessment of high-density lipoprotein heterogeneity. Clin Chem 194;40: 1554–8
   Google Scholar
• Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ. Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients. J Lipid Res 2002;43:1701–7
   PubMed Web of Science ®Google Scholar
• Asztalos B, Horvath K, McNamara J, Roheim P, Rubinstein J, Schaefer E. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 2002;164:361–9
   PubMed Web of Science ®Google Scholar
• Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 2000;20: 189–97
   Google Scholar
• Athyros VG, Papageorgiou AA, Elisaf M, Mikhailidis DP. Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin 2003;19:615–7
   PubMed Web of Science ®Google Scholar
• Kuvin JT, Patel AR, Sidhu M, et al. Relation between high-density lipoprotein cholesterol and peripheral vasomotor function. Am J Cardiol 2003;92:275–9
   PubMed Web of Science ®Google Scholar
• Kuvin JT, Patel AR, Rämet ME, Pandian NG, Mendelsohn ME, Karas RH. A novel mechanism for the beneficial vascular effects of high-density cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 2002;144:165–72
   Google Scholar
• Elisaf M, Mikhailidis DP: Statins and renal function. Angiology 2002;53:493–502
   PubMed Web of Science ®Google Scholar
• Joyce M, Kelly C, Winter D, et al. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion. J Surg Res 2001;101:79–84
   PubMed Web of Science ®Google Scholar
• Kaplan RC, Heckbert SR, Furberg CD, et al. Predictors of subsequent coronary events, stroke, and death among survivors of first myocardial infarction. J Clin Epidemiol 2002;55:654–64
   PubMed Web of Science ®Google Scholar
• Youssef F, Seifalian AM, Jagroop A, Myint F, Baker D, Mikhailidis DP, Hamilton G. The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT). Eur J Vasc Endovasc Surg 2002;23:358–64
   PubMed Web of Science ®Google Scholar
• Youssef F, Gupta P, Seifalian AM, Myint F, Mikhailidis DP, Hamilton G. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology 2004;55:53–62
   PubMed Web of Science ®Google Scholar
• Sinzinger H, Kritz H, Furberg CD. Atorvastatin reduces microalbuminouria in patients with familial hypercholesterolemia and normal glucose tolerance. Med Sci Monit 2003;9:88–92
   Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005–16
   PubMed Web of Science ®Google Scholar